Global and regional burden of attributable and associated bacterial antimicrobial resistance avertable by vaccination: modelling study

Chaelin Kim,[1] Marianne Holm,[1] Isabel Frost,[2] Mateusz Hasso-Agopsowicz,[2] Kaja Abbas[3]

[1] International Vaccine Institute, Seoul, Republic of Korea

[2] World Health Organization, Geneva, Switzerland

[3] London School of Hygiene & Tropical Medicine, London, United Kingdom

Corresponding author: chaelin.kim@ivi.int / ckim0509@gmail.com

Summary

Background: Antimicrobial resistance (AMR) is a global health threat with 1.27 million deaths attributable to bacterial AMR and 4.95 million deaths associated with bacterial AMR in 2019. Our aim is to estimate the vaccine avertable bacterial AMR burden based on profiles of existing and future vaccines at the regional and global levels by pathogen and infectious syndromes.

Methods: We developed a static proportional impact model to estimate the vaccination impact in terms of reduction in age-specific AMR burden estimates for 2019 from the Global Research on AntiMicrobial resistance project in direct proportion to efficacy, coverage, target population for protection, and duration of protection of existing and potential future vaccines. We estimated vaccine avertable deaths and disability-adjusted life-years (DALYs) attributable to and associated with AMR for 15 bacterial pathogens by region, infectious syndrome, and pathogen with 95% uncertainty intervals (UIs) for two scenarios – baseline scenario for primary vaccination of specific age-groups and high-potential scenario that includes additional age groups at risk.

Findings: In the baseline scenario, we estimated that vaccines against the 15 pathogens could avert 0.49 (0.47 - 0.51) million deaths and 28 (27 - 29) million DALYs associated with bacterial AMR, and 0.15 (0.14 - 0.16) million deaths and 7.5 (7.0 - 7.9) million DALYs attributable to AMR globally in 2019. We estimated vaccine avertable deaths associated with AMR to be highest for an improved vaccine against *Streptococcus pneumoniae* with 0.12 (0.11 - 0.14) million deaths averted, by infectious syndrome for lower respiratory infections with 0.16 (0.15 - 0.17) million deaths averted, and in the WHO Africa region with 0.16 (0.15 - 0.17) million deaths averted. In the high-potential scenario, we estimated that vaccines against a subset of 7 pathogens could avert an additional 1.0 (0.99 - 1.0) million deaths and 30 (30 - 31) million DALYs associated with AMR, and 0.27 (0.27 - 0.28) million deaths and 8.2 (8.0 - 8.5) million DALYs attributable to AMR globally in 2019.

Interpretation: Increased coverage of existing vaccines and the development of new vaccines are effective means to reduce AMR. We recommend that the vaccine avertable burden of AMR be included in the full value of vaccine assessments, and that stakeholders include this evidence to inform and prioritise decisions throughout the end-to-end continuum from discovery and clinical development to investment, development, introduction, and sustainability of new vaccines with equitable access.

Funding: Bill & Melinda Gates Foundation (INV-006816)

Research in context

Evidence before the study

We searched PubMed with the search terms “vaccine impact" AND ("AMR" OR "antimicrobial resistance" OR "antibiotic resistance")” on 6 May 2022 with no language restrictions. This returned 14 articles and was complemented by searching the references in three systematic reviews and a scoping review on measuring the link between vaccines and antimicrobial resistance in low resource settings. Evidence was scarce with only limited evidence on the impact of vaccines against *Haemophilus influenzae* type b, rotavirus, *Streptococcus pneumoniae*, *Salmonella* Typhi and influenza on AMR in specific settings. To our knowledge, this is the first study to estimate attributable and associated bacterial AMR burden avertable by vaccination for a combined set of existing and new vaccines in the pipeline by pathogen, infectious syndrome, and region.

Added value of this study

In 2019, based on our model-based estimates of existing and future vaccines for 15 pathogens (*Acinetobacter baumannii*, *Enterococcus faecium*, *Escherichia coli*, Group A *Streptococcus*, *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Mycobacterium tuberculosi*s, *Neisseria gonorrhoeae*, non-typhoidal *Salmonella*, *Pseudomonas aeruginosa*, *Salmonella* Paratyphi, *Salmonella* Typhi, *Shigella* spp., *Staphylococcus aureus*, and *Streptococcus pneumoniae*), the vaccine avertable mortality burden associated with bacterial AMR were highest for an improved vaccine against *Streptococcus pneumoniae*, lower respiratory infections by infectious syndrome, and in the WHO Africa region. This evidence assists in targeting areas for scaling up of existing vaccines and prioritise development of new vaccines with high potential for impact on lowering AMR burden by pathogen, infectious syndrome, and region.

Implications of all the available evidence

While the existing vaccines against *Streptococcus pneumoniae*, *Haemophilus influenzae* type b, and *Salmonella* Typhi are effective tools in directly averting bacterial AMR, there is a strong need to scale up coverage of these existing vaccines to reach their full potential and achieve the strategic priority on coverage and equity of Immunisation Agenda 2030. Further, typhoid conjugate vaccine introductions in high burden countries should be accelerated. New vaccines in the pipeline, including the late-stage development of vaccines against *Shigella* spp. and *Mycobacterium tuberculosis*, have good potential to avert a significant burden of bacterial AMR regionally and globally. We recommend critical assessment on the feasibility of developing new vaccines, including for *Klebsiella pneumoniae*, for targeting the growing global public health threat of AMR.

Introduction

Since the discovery of the first antibiotic penicillin in 1928, antimicrobials have been used to treat bacteria, fungi, parasites, and viruses, saving countless lives. However, antimicrobial resistance (AMR) is a growing global public health threat in the 21st century.[1] Resistance occurs through pathogen evolution, either naturally over time or acquired by the use of antimicrobial drugs, which render these drugs ineffective and increase the risk of morbidity and mortality. While access to antibiotic and antimicrobial drugs in low- and middle-income countries to treat drug-resistant infections continues to be a challenge, misuse of antimicrobials along with lack of access to clean water, sanitation and hygiene (WASH) and effective infection prevention and control (IPC) measures have fuelled the emergence and spread of AMR globally. The AMR threat challenges the health gains of the 20th century in treating infections and lowering the burden of infectious diseases. To assess the global threat of this growing silent pandemic, the UK government commissioned a review on AMR to tackle drug-resistant infections. The 2014 report projected that if AMR is not controlled, it would lead to significant impact on health with 10 million AMR-related deaths annually and macroeconomic consequences with a cumulative economic loss of US$ 100 trillion by 2050.[2]

Vaccination, when used in conjunction with other preventive measures, has the potential to significantly reduce AMR transmission through several pathways.[3] First, vaccination has a direct influence on the health burden of AMR by preventing the emergence and transmission of drug-resistant and drug-sensitive infections, and the associated antibiotic use. Second, vaccines have an indirect influence by reducing resistant infections in unvaccinated populations through herd immunity. Third, vaccines can also prevent infections where antimicrobials are not indicated but often wrongly prescribed, such as primary viral infections, thereby reducing antibiotic misuse and overuse. Finally, vaccines can give longer-term health benefits in preventing infections and resistance to vaccines is rarely observed.[4]

Haemophilus influenzae type b (Hib), rotavirus, pneumococcal, typhoid and influenza vaccines have been directly associated with reduction of resistance, antibiotic use and related clinical complications.[5–7] The introduction of Hib conjugate vaccines has been associated with decreasing the prevalence of beta-lactamase production among patients with respiratory tract infections in the United States.[8] Rotavirus and pneumococcal vaccines are estimated to prevent 13.6 million and 23.8 million episodes of antibiotic-treated illness among under-5-year old children in low- and middle-income countries (LMICs) annually, based on the current levels of vaccination coverage.[9] With universal coverage of both vaccines, an additional 40 million episodes of antibiotic-treated illness could potentially be averted. In an outbreak setting of extensively drug-resistant (XDR) *Salmonella* Typhi in Pakistan during 2018-2019, the typhoid conjugate vaccine (Typbar-TCV) had 55%, 95%, and 97% effectiveness against suspected *S* Typhi, culture-confirmed *S* Typhi, and XDR *S* Typhi.[10] There is high and moderate certainty evidence that influenza vaccination reduced days of antibiotic use among adults and children by 28% and 38% respectively, based on a systematic review and meta-analysis of randomised clinical trials from 1998 to 2018.[11]

The Global Research on AntiMicrobial (GRAM) resistance project estimated the deaths and disability-adjusted life-years (DALYs) attributable to and associated with resistance by replacing all drug-resistant infections with susceptible infection or no infection, respectively. It estimated that 1.27 (95% UI: 0.91 - 1.7) million deaths and 47.9 (35 - 64) million DALYs were attributable to bacterial AMR and 4.95 (3.6 - 6.6) million deaths and 192 (146 - 248) million DALYs were associated with bacterial AMR in 2019.[12] Despite the significant potential impact of vaccination in lowering AMR, evidence is limited due to the methodological difficulties and challenges in obtaining data on the health burden associated with AMR in order to calculate this impact.[5,13] Such evidence will be valuable to inform improvements in the coverage of existing vaccines and prioritise research and funding for new vaccines in the pipeline. To address this evidence gap, our aim is to analyse the findings from the GRAM project and estimate the vaccine avertable bacterial AMR burden based on the profiles of existing and future vaccines by pathogen and infectious syndromes at the regional and global levels in 2019.

Methods

AMR burden data

We used the bacterial AMR burden estimates from the Global Research on AntiMicrobial resistance (GRAM) project which provided data for age-specific deaths and DALYs associated with and attributable to AMR by pathogen, infectious syndrome, and region.[12] These comprehensive estimates of bacterial AMR burden were based on statistical predictive modelling of data from systematic reviews, surveillance systems, hospital systems, and other sources to generate estimates for 23 pathogens and 88 pathogen-drug combinations for 204 countries in 2019. Two sets of estimates are presented – burden attributed to AMR, that is deaths and DALYs that could be averted if all drug-resistant infections would be replaced by drug-sensitive infections; and burden associated with AMR, that is deaths and DALYs that could be averted if all drug-resistant infections would be replaced by no infections, which is the case for vaccines.

Vaccine profiles

We focused our analysis on 15 pathogens - *Acinetobacter baumannii*, *Enterococcus faecium*, *Escherichia coli*, Group A *Streptococcus*, *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Mycobacterium tuberculosi*s, *Neisseria gonorrhoeae* (morbidity and no mortality), non-typhoidal *Salmonella*, *Pseudomonas aeruginosa*, *Salmonella* Paratyphi, *Salmonella* Typhi, *Shigella* spp., *Staphylococcus aureus*, and *Streptococcus pneumoniae*. We selected pathogens that are part of the WHO evaluation of the value of vaccines in preventing AMR. We used vaccine profiles (see Table 1), which comprise the vaccine target population, efficacy, coverage in the target group, duration of protection, and disease presentation prevented. For the existing vaccines against *Haemophilus influenzae* type b, *Streptococcus pneumoniae*, and *Salmonella* Typhi, the vaccine profiles expand coverage of the current vaccines in order to meet the strategic priority on coverage and equity of Immunisation Agenda 2030.[14] For vaccines that are not yet available, hypothetical profiles were developed based on preferred product characteristics (PPCs),[15] target product profiles (TPPs), attributes of advanced vaccine candidates, and expert consultations with WHO working groups, PATH, and pathogen experts. Some pathogens have multiple disease presentations and would require different vaccines to prevent different disease presentations. As such, these pathogens have more than one vaccine profile.

Modelling process

We developed a static proportional impact model to estimate the vaccination impact in terms of reduction in age-specific AMR burden estimates for 2019 from the GRAM project. The burden reduction was in direct proportion to efficacy, coverage, target population for protection, and duration of protection of existing and potential future vaccines.[16] We estimated vaccine avertable deaths and DALYs attributable to and associated with AMR by region, infectious syndrome, and pathogen with 95% uncertainty intervals (UIs) for two scenarios – baseline scenario (for 15

pathogens) for primary vaccination of specific age-groups and high-potential scenario (for a subset of 7 pathogens) that includes additional age groups at risk.

Table 1 describes the vaccine profiles with the corresponding product characteristics for efficacy and duration of protection for vaccine-derived immunity, and coverage and target population for the baseline and high-potential scenarios. In the *baseline* scenario, we estimated the vaccine avertable burden from the age of vaccination and the vaccine-derived immunity would sustain for the duration of protection of the corresponding vaccines. For pathogens with a highly uncertain vaccine target population or feasibility of vaccine delivery, we estimated an additional *high-potential* scenario which assumed that individuals at risk (including additional age groups at risk) would be vaccinated to protect against corresponding disease presentations. This was applicable to vaccines against *Acinetobacter baumannii*, *Enterococcus faecium*, Extraintestinal Pathogenic *Escherichia coli* (ExPEC), *Klebsiella pneumoniae (all syndromes)*, *Pseudomonas aeruginosa*, and *Staphylococcus aureus*. For *Streptococcus pneumoniae*, we explored the high-potential scenario by administering a vaccine to an elderly population with the highest disease burden.

The GRAM project estimates for AMR burden do not differentiate by *Escherichia Coli* strains, instead, the AMR burden estimates were stratified by symptoms. Since enterotoxigenic *E.coli* (ETEC) and extraintestinal pathogenic *E.coli* (ExPEC) are the two major *E. coli* strains that cause diarrhoea, we calculated the proportional contribution of ETEC to the AMR burden due to *E.coli* causing diarrhoea and then estimate the impact of the ETEC vaccine on reducing this burden among under 5-year-old children. Similarly, the GRAM project estimates of AMR burden for *Haemophilus influenzae* were not stratified by stereotypes. However, *Haemophilus influenzae* type b (Hib) accounts for 95% of all invasive diseases caused by *Haemophilus influenzae*.[17] Thereby, we used 95% proportion of the total *Haemophilus influenzae* burden to calculate the Hib specific AMR burden.

For the existing *Haemophilus influenzae* type B (Hib) and pneumococcal conjugate (PCV) vaccines, we estimated the pre-vaccination (i.e., no vaccination) burden associated and attributable to AMR in 2019 using the estimates of efficacy and coverage in 2019. We used the vaccine coverage for Hib and PCV from WHO/UNICEF Estimates of National Immunization Coverage (WUENIC)[18] and demography data from the United Nations World Population Prospects (UNWPP)[19] to estimate the vaccine coverage at the regional level. We used the vaccine efficacy estimates for the first dose, second dose, third doses scheduled at 6, 10, and 14 weeks - 59%, 92%, and 93% respectively for the Hib vaccine,[20] and 29%, 58%, and 58% respectively for the PCV vaccine.[21,22] By applying the vaccine efficacies and regional coverage to the AMR burden data in 2019, we estimated the increase in AMR burden for the counterfactual scenario of no vaccination in direct proportion to efficacy, coverage, target population for protection, and duration of protection. The global and regional coverage of typhoid conjugate vaccine and the post-vaccination impact was minimal in 2019 [23] and thereby did not warrant additional estimation for the counterfactual scenario of no vaccination.

195 **Uncertainty analysis**

We conducted a Monte Carlo simulation of 1000 runs to propagate the uncertainty in the AMR burden data through the modelling process to estimate the uncertainty in our projected outcomes of vaccination impact. We provide summary estimates in terms of vaccine avertable deaths and DALYs attributable to and associated with AMR by region, infectious syndrome, and pathogen with
200 95% uncertainty intervals (UIs) for the baseline and high-potential scenarios.

Ethics approval

This study was approved by the ethics committee (Ref 26896) of the London School of Hygiene & Tropical Medicine. All authors had full access to all the data in the study and final responsibility for the decision to submit for publication. We conducted our analysis using the R programming
205 language for statistical computing,[24] and the repository for the data and software code of this modelling study are publicly accessible at https://github.com/vaccine-impact/vaccine_amr.

Results

Vaccine impact on global AMR burden

At the global level in 2019 for the baseline scenario, we estimated that vaccines against the 15 pathogens (analysed in this study) could avert 0.49 (95% UI: 0.47 - 0.51) million deaths and 28 (27 - 29) million DALYs associated with AMR, and 0.15 (0.14 - 0.16) million deaths and 7.5 (7.0 - 7.9) million DALYs attributable to AMR. In the high-potential scenario, we estimated that vaccines against a subset of 7 pathogens could avert an additional 1.0 (0.99 - 1.0) million deaths and 30 (30 - 31) million DALYs associated with AMR, and 0.27 (0.27 - 0.28) million deaths and 8.2 (8.0 - 8.5) million DALYs attributable to AMR globally.

Vaccine impact on AMR burden by pathogen

Figure 1 and Table 2a present the vaccine avertable burden attributable to and associated with AMR in 2019 for each of the vaccine profiles at the global level for the baseline scenario. For pathogens with licensed vaccines, we estimated that vaccination against *Streptococcus pneumoniae* at 2019 coverage levels averted 52 (47 - 57) thousand deaths and 4.5 (4.1 - 5.1) million DALYs associated with AMR in 2019. By reaching the WHO recommended coverage level of 90% globally, 68 (62 - 75) thousand deaths and 6.0 (5.4 - 6.6) million DALYs associated with AMR could be averted. Expanding the coverage to elderly populations would increase the vaccination impact to avert 80 (74 - 87) thousand deaths. We estimated that vaccination against *Haemophilus influenzae* at 2019 coverage levels averted 19 (17 - 21) thousand deaths and 1.6 (1.5 - 1.8) million DALYs associated with AMR in 2019. At 90% coverage globally, 22 (19 - 24) thousand deaths and 1.9 (1.7 - 2.1) million DALYs associated with AMR could be averted. We estimated that wider introduction and scale-up of vaccination against *Salmonella* Typhi could avert 34 (28 - 45) thousand deaths and 2.8 (2.3 - 3.5) million DALYs associated with AMR in 2019.

For pathogens with hypothetical vaccine profiles (developed by experts or provided in preferred product characteristics), we estimated that an improved vaccine against *Streptococcus pneumoniae* (70% efficacy against BSI, CNS and cardiac infections, 50% efficacy against LRI, given to 90% of infants at six weeks of life) would have a relatively highest impact by averting 0.12 (0.11 - 0.14) million deaths and 11 (9.7 - 12) million DALYs associated with AMR in 2019. A vaccine against *Mycobacterium tuberculosis* that meets WHO's PPC criteria of 80% efficacy, given to infants, with life-long immunity or boosting, would avert 0.12 (0.11 - 0.13) million deaths and 4.6 (4.2 - 5.0) million DALYs associated with AMR. A M72-like vaccine against *Mycobacterium tuberculosis* given to adolescents and older population with life-long immunity or boosting would avert 74 (67 - 82) thousand deaths and 2.9 (2.6 - 3.1) million DALYs associated with AMR. A vaccine against all disease presentations of *Klebsiella pneumoniae* infection given to infants would avert 65 (60 - 71) thousand deaths and 3.7 (3.4 - 4.0) million DALYs associated with AMR.

In the high-potential scenario (see Table 2b), we estimated that vaccination of at-risk individuals

across all age groups against *Klebsiella pneumoniae* infection could avert 0.32 (0.31 - 0.33) million deaths and 14 (13 - 14) million DALYs associated with AMR in 2019. Vaccination of at-risk individuals against *Staphylococcus aureus* could avert 0.32 (0.31 - 0.33) million deaths and 11 (10 - 11) million DALYs associated with AMR, and vaccination against *Acinetobacter baumannii* could avert 0.22 (0.20 - 0.23) million deaths and 6.0 (5.7 - 6.3) million DALYs associated with AMR.

Vaccine impact on AMR burden by infectious syndrome

Figure 2 shows the vaccine avertable deaths and DALYs attributable to and associated with bacterial AMR for the different infectious syndromes in 2019 at the global level in the baseline scenario. We estimated vaccine avertable mortality associated with bacterial AMR to be highest for lower respiratory infections at 0.16 (0.15 - 0.17) million deaths and 11 (10 - 12) million DALYs for the baseline scenario, followed by tuberculosis at 0.12 (0.11 - 0.13) million deaths and 4.6 (4.2 - 5.0) million DALYs and bloodstream infections at 0.11 (0.10 - 0.12) million deaths and 5.6 (5.2 - 6.2) million DALYs in 2019. In the high-potential scenario, vaccine avertable deaths were highest for tuberculosis, cardiac infections, and intra-abdominal infections, and vaccine avertable DALYs were highest for urinary tract infections, bloodstream infections, and CNS infections.

For each infectious syndrome, we stratified the vaccine avertable AMR burden for deaths and DALYs by pathogen in the baseline scenario, as shown in Figure 3 (and Figure A1 in the appendix). *Streptococcus pneumoniae*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, and *Haemophilus influenzae* type b account for most of the vaccine avertable AMR burden associated with lower respiratory infections. *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Escherichia coli*, and *Streptococcus pneumoniae* account for most of the vaccine avertable AMR burden associated with bloodstream infections.

Vaccine impact on AMR burden at the regional level

Table 3 and Figure 4 show the vaccine avertable deaths and DALYs attributable to and associated with bacterial AMR at the regional levels in 2019 for the baseline scenario. We estimated the vaccine avertable burden associated with bacterial AMR to be highest in the WHO Africa region at 0.16 (0. 15 - 0.17) million deaths and 12 (11 - 13) million DALYs, followed by the WHO South-East Asia region at 0.15 (0.14 - 0.17) million deaths and 7.3 (6.6 - 8.2) million DALYs in 2019. The vaccine avertable AMR burden for the WHO Africa and South-East Asia regions account for around two-thirds of the vaccine avertable AMR burden globally in 2019. In the high-potential scenario, we estimated that vaccines would avert an additional 0.15 (0.15 - 0.16) million deaths and 7.4 (6.9 - 8.0) million DALYs associated with AMR in the WHO Africa region, and 0.26 (0.25 - 0.28) million deaths and 8.5 (8.1 - 8.9) million DALYs associated with AMR in the WHO South-East Asia region.

Discussion

We estimated vaccine avertable disease burden attributable to and associated with AMR for existing and new vaccines in the pipeline by pathogen, infectious syndrome, and region based on the most recent, comprehensive estimates of the global burden of AMR. The AMR burden avertable by vaccination in 2019 were highest for the WHO Africa and South-East Asia regions, for lower respiratory infections, tuberculosis, and bloodstream infections by infectious syndromes, and for *Streptococcus pneumoniae*, *Mycobacterium tuberculosis*, and *Klebsiella pneumoniae* by pathogen.

The GRAM project estimated age-specific deaths and DALYs attributable to and associated with AMR by pathogen, infectious syndrome, and region for 2019.[12] Two counterfactual scenarios were used where drug-resistant burden were replaced by a drug-susceptible burden (attributable AMR burden), and drug-resistant burden were replaced by no disease burden (associated AMR burden). As vaccines prevent drug-resistant and drug-susceptible burden, we infer that the associated AMR burden as the appropriate metric for measuring the impact of vaccination on AMR burden.

Our estimates show the impact of existing vaccines (pneumococcal (PCV), *Haemophilus influenzae* type b (Hib), and typhoid (TCV) conjugate vaccines) on reducing AMR burden attributable to and associated with *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Salmonella* Typhi respectively. For PCV and Hib vaccines, we estimated the impact at current coverage and at WHO recommended coverage of 90%. For PCV, we also estimated the additional impact gained by immunising elderly populations. We highlight the critical need to scale up existing vaccines to high and equitable immunisation coverage, and the acceleration of TCV introductions in high burden countries.

Our estimates show that vaccines can contribute towards preventing a significant proportion of the AMR burden for pathogens which have vaccines in late-stage clinical development with clear attributes or published preferred product characteristics or target product profiles, such as for *Escherichia coli* and *Mycobacterium tuberculosis*. To accelerate the anticipated licensure of these products, novel regulatory and policy mechanisms should be developed to accelerate the approval and use of these vaccines to prevent AMR. Vaccine developers and regulatory authorities should agree on the required data that need to be collected during clinical trials to ensure timely approval and licensure.

For the remaining pathogens that have vaccine candidates in early stages of the clinical development, or no vaccines in the pipeline, we recommend investigating the vaccine development from biological challenges to feasibility in terms of product development, market access, and product implementation. Based on the estimated high vaccine avertible burden associated with AMR for *Klebsiella pneumoniae*, *Staphylococcus aureus*, and *Acinetobacter baumannii*, we urgently call for studies to enhance biological understanding and improve the feasibility of developing vaccines for these pathogens.

We estimated a lower vaccine avertable burden attributable to and associated with AMR for *Shigella* spp., non-typhoidal *Salmonella*, *Salmonella* Paratyphi, Group A *Streptococcus*, and *Neisseria gonorrhoeae*. The lower burden of deaths and DALYs attributable to and associated with AMR for these pathogens can be partially explained by the lower number of deaths and DALYs due to drug-sensitive and drug-resistant infections when compared to other pathogens in this analysis. The comprehensive assessment of the value of vaccines against AMR should include indicators beyond mortality such as the impact on antibiotic use, economic burden, and social equity. Group A *Streptococcus* is associated with high antibiotic use which drives resistance in focal and non-focal pathogens, however, this impact is not incorporated in this analysis. Repeated *Shigella* infections result in long-term morbidity which can be further exacerbated by resistant infections,[25] and full value of vaccine assessments should consider the propensity for resistance to rapidly emerge, as seen for *Neisseria gonorrhoea* in past decades.[26]

We estimated vaccine avertable AMR burden for baseline and high-potential scenarios. We recognise that the high-potential scenario is optimistic given the unanswered questions about feasibility of producing vaccines with long-term immunity and timely delivery to populations at risk, such as patients in hospitals undergoing elective surgeries. We included the high-potential scenario to highlight the potential impact that vaccines could have if challenges around vaccine development and delivery were to be resolved.

Our analysis should be followed up with detailed vaccine-specific analyses, considering pathogen biology and transmission, and accounting for varied disease burden patterns across the spatial and temporal scales. Fu *et al.* modelled the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine with 50% efficacy to estimate that a future TB vaccine could avert 10% of rifampicin-resistant TB cases and 7.3% of deaths over 2020-2035 in 30 countries that accounted for 90% of global rifampicin-resistant TB incidence in 2018.[27] Our analysis predicts that a similar vaccine could avert relatively higher number of deaths associated with resistant TB annually in comparison to the projections of Fu et al. Our analysis assumes life-long protection or administration of booster doses, as outlined in the WHO PPC [28], whereas Fu et al assume single vaccine administration with 10-year protection. Fu et al analysed 30 countries with the highest disease prevalence and focused on rifampicin resistant TB, while our analysis was global and looked at all types of resistant TB. Andrejko et al conducted a systematic review and meta-analysis to assess the susceptibility of paediatric pneumococcal isolates to various antimicrobial drugs before and after PCV implementation across all regions and estimated significant reduction in resistance of 11.5% to penicillin, 9.7% to sulfamethoxazole-trimethoprim, and 7.5% to third-generation cephalosporins among the isolates.[29] Birger et al modelled the introduction of TCV for children aged 9 months into the routine immunisation programme along with a catch-up campaign up to age 15 years in 73 Gavi-supported countries and predicted that 46-74% of all typhoid fever cases and 16% of antimicrobial-resistant typhoid fever would be averted by vaccination.[30]

Our study has limitations. First, since we included the direct effect of vaccination but excluded

350 indirect effect and transmission dynamics of AMR pathogens, our vaccine impact estimates on averted AMR burden are conservative. Second, our analysis focused on 15 bacterial pathogens and additional pathogens included in the GRAM project such as *Enterobacter* spp., Group B *Streptococcus*, *Enterococcus feacalis*, *Proteus* spp., *Citrobacter* spp., *Morganella* spp. were excluded. However, inclusion of these pathogens appears unlikely to significantly affect our overall inferences
355 considering that the included 15 pathogens are responsible for the majority of the AMR burden. Third, while our analysis was based on the estimates generated by the GRAM project, which represents the most comprehensive estimates of bacterial AMR burden to date, limited input data to the GRAM project especially from low- and middle-income countries is a significant data gap that necessitates newer surveillance data and platforms to inform the updates, validity, and confidence
360 in the estimates of the GRAM project. In particular, GRAM estimates for tuberculosis do not include tuberculosis associated with HIV. Finally, we did not consider the impact of viral vaccines on reducing the AMR drivers of antibiotic misuse and overuse.[9,11,31,32]

The value of vaccines in preventing AMR should be systematically considered in the decision-making process during scale-up of existing vaccines and introduction of new vaccines. Vaccines should be
365 explicitly incorporated as tools to combat AMR into National Action Plans on AMR and National Immunisation Strategies. Appropriate communication and training should be developed to inform vaccine recipients, health professionals, and decision-makers about the value and mechanisms by which vaccines prevent AMR. For new vaccines in the pipeline and future vaccines, we recommend vaccine avertable burden of AMR to be included in the full value of vaccine assessments, and
370 stakeholders are made aware of this value to inform and prioritise decisions throughout the end-to-end continuum from discovery and clinical development to investment, development, introduction, and sustainability of new vaccines with equitable access.

Role of the funding source

This study was funded by the Bill & Melinda Gates Foundation (INV-006816). The funders were not involved in the study design, data collection, data analysis, data interpretation, writing of the report, and the decision to submit for publication. All authors had full access to all the data in the study and final responsibility for the decision to submit for publication.

Contributors

CK, MH, IF, MHA, and KA conceptualised and designed the study. IF and MHA compiled the data sets. CK developed the proportional impact model and software and conducted the analysis. CK and KA wrote the first draft, and all authors contributed to reviewing and editing of the manuscript and have approved the final version.

Acknowledgements

We thank Mohsen Naghavi, Gisela Robles Aguilar, and Eve Wool of the Institute for Health Metrics and Evaluation for sharing the bacterial AMR burden data. We thank Ramanan Laxminarayan (Center for Disease Dynamics, Economics & Policy) and Padmini Srikantiah (Bill & Melinda Gates Foundation) for helpful discussions. We thank John Clemens, Nimesh Poudyal, and Raphael Zellweger at the International Vaccine Institute for their review and feedback on this article.

Declaration of interests

We declare no competing interests. Where authors are identified as personnel of the WHO, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy, or views of the WHO.

ORCID

CK (0000-0001-7720-3349), MH (0000-0002-0747-4116), IF (0000-0002-0095-0845), MHA (0000-0003-4137-4685), KA (0000-0003-0563-1576)

Bibliography

1 WHO. Global action plan on antimicrobial resistance. World Health Organization, 2015.

2 O'Neill J (chair). Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. The Review on Antimicrobial Resistance, 2014.

3 Bloom DE, Black S, Salisbury D, Rappuoli R. Antimicrobial resistance and the role of vaccines. *Proc Natl Acad Sci USA* 2018; **115**: 12868–71.

4 Kennedy DA, Read AF. Why the evolution of vaccine resistance is less of a concern than the evolution of drug resistance. *Proc Natl Acad Sci USA* 2018; **115**: 12878–86.

5 Holm M, Zellweger RM, Poudyal N, Smith KH, Joh HS, Marks F. Measuring the link between vaccines and antimicrobial resistance in low resource settings – limitations and opportunities in direct and indirect assessments and implications for impact studies. *Front Trop Dis* 2022; **3**. DOI:10.3389/fitd.2022.805833.

6 Tomczyk S, Lynfield R, Schaffner W, *et al.* Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine. *Clin Infect Dis* 2016; **62**: 1119–25.

7 Adam HJ, Richardson SE, Jamieson FB, Rawte P, Low DE, Fisman DN. Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination. *Vaccine* 2010; **28**: 4073–8.

8 Heilmann KP, Rice CL, Miller AL, *et al.* Decreasing prevalence of beta-lactamase production among respiratory tract isolates of Haemophilus influenzae in the United States. *Antimicrob Agents Chemother* 2005; **49**: 2561–4.

9 Lewnard JA, Lo NC, Arinaminpathy N, Frost I, Laxminarayan R. Childhood vaccines and antibiotic use in low- and middle-income countries. *Nature* 2020; **581**: 94–9.

10 Yousafzai MT, Karim S, Qureshi S, *et al.* Effectiveness of typhoid conjugate vaccine against culture-confirmed Salmonella enterica serotype Typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: a cohort study. *Lancet Glob Health* 2021; **9**: e1154–62.

11 Buckley BS, Henschke N, Bergman H, *et al.* Impact of vaccination on antibiotic usage: a systematic review and meta-analysis. *Clin Microbiol Infect* 2019; **25**: 1213–25.

12 Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet* 2022; **399**: 629–55.

13 Clift C, Salisbury DM. Enhancing the role of vaccines in combatting antimicrobial resistance. *Vaccine* 2017; **35**: 6591–3.

14 WHO. Immunization Agenda 2030: A global strategy to leave no one behind. 2020. http://www.immunizationagenda2030.org/ (accessed May 17, 2021).

15 WHO. Preferred Product Characteristics (PPCs) and Target Product Profiles (TPPs). 2022. https://www.who.int/teams/immunization-vaccines-and-biologicals/product-and-delivery-research/ppcs (accessed May 7, 2022).

16 Echeverria-Londono S, Li X, Toor J, *et al.* How can the public health impact of vaccination be estimated? *BMC Public Health* 2021; **21**: 2049.

17 WHO. Immunological Basis for Immunization Series: Module 9: Haemophilus influenzae type b.

2007. https://www.who.int/publications/i/item/who-immunological-basis-for-immunization-series-module-9-haemophilus-influenzae-type-b (accessed April 22, 2022).

18 WHO, UNICEF. WUENIC (WHO/UNICEF Estimates of National Immunization Coverage) estimates - Vaccines monitoring system 2019 Global Summary Reference Time Series. 2019. https://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragedtp3.html (accessed April 19, 2020).

19 United Nations. World Population Prospects 2019, United Nations Department of Economic and Social Affairs Population Division. 2019. https://population.un.org/wpp/ (accessed Nov 18, 2019).

20 Griffiths UK, Clark A, Gessner B, *et al.* Dose-specific efficacy of Haemophilus influenzae type b conjugate vaccines: a systematic review and meta-analysis of controlled clinical trials. *Epidemiol Infect* 2012; **140**: 1343–55.

21 Lucero MG, Dulalia VE, Nillos LT, *et al.* Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. *Cochrane Database Syst Rev* 2009; : CD004977.

22 Mahon BE, Hsu K, Karumuri S, *et al.* Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. *Vaccine* 2006; **24**: 2514–20.

23 Neuzil KM, Pollard AJ, Marfin AA. Introduction of typhoid conjugate vaccines in Africa and Asia. *Clin Infect Dis* 2019; **68**: S27–30.

24 R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2019.

25 Ranjbar R, Farahani A. Shigella: Antibiotic-Resistance Mechanisms And New Horizons For Treatment. *Infect Drug Resist* 2019; **12**: 3137–67.

26 Workowski KA, Berman SM, Douglas JM. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. *Ann Intern Med* 2008; **148**: 606–13.

27 Fu H, Lewnard JA, Frost I, Laxminarayan R, Arinaminpathy N. Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine. *Nat Commun* 2021; **12**: 424.

28 WHO. WHO preferred product characteristics for new tuberculosis vaccines. World Health Organization, 2018.

29 Andrejko K, Ratnasiri B, Hausdorff WP, Laxminarayan R, Lewnard JA. Antimicrobial resistance in paediatric Streptococcus pneumoniae isolates amid global implementation of pneumococcal conjugate vaccines: a systematic review and meta-regression analysis. *Lancet Microbe* 2021; **2**: e450–60.

30 Birger R, Antillón M, Bilcke J, *et al.* Estimating the effect of vaccination on antimicrobial-resistant typhoid fever in 73 countries supported by Gavi: a mathematical modelling study. *Lancet Infect Dis* 2022; published online Feb 3. DOI:10.1016/S1473-3099(21)00627-7.

31 Doherty TM, Hausdorff WP, Kristinsson KG. Effect of vaccination on the use of antimicrobial agents: a systematic literature review. *Ann Med* 2020; **52**: 283–99.

32 Holmes AH, Moore LSP, Sundsfjord A, *et al.* Understanding the mechanisms and drivers of antimicrobial resistance. *Lancet* 2016; **387**: 176–87.

Tables

Table 1. Vaccine profiles. Product characteristics for efficacy and duration of protection for vaccine-derived immunity, and coverage and target population (age of vaccination) for current and future vaccines against bacterial pathogens. The baseline scenario includes 15 pathogens, and the high-potential scenario includes a subset of 7 pathogens.

(Bone and joint infections = infections of bones, joints, and related organs; BSI = bloodstream infections; cardiac infections = endocarditis and other cardiac infections; CNS infections = meningitis and other bacterial CNS infections; intra-abdominal infections = peritoneal and intra-abdominal infections; LRI and thorax infections = lower respiratory infections and all related infections in the thorax; bacterial skin infections = bacterial infections of the skin and subcutaneous systems; typhoid, paratyphoid, and iNTS = typhoid fever, paratyphoid fever, and invasive non-typhoidal *Salmonella* spp; UTI = urinary tract infections and pyelonephritis)

Pathogen	**Disease presentation**	**Vaccine**			**Vaccination scenarios** (age of vaccination)		**Justification**
		Efficacy (%)	**Coverage (%)**	**Duration of protection**	**Baseline scenario**	**High-potential scenario**	
Acinetobacter baumannii - BSI†	BSI	70	70	5 years	6 weeks, elderly age group with highest burden	All age groups	Hypothetical vaccine based on expert opinion
Acinetobacter baumannii - all	All (Bacterial skin infections, BSI, Cardiac infections, LRI and thorax infections, UTI)	70	70	5 years	6 weeks, elderly age group with highest burden	All age groups	Hypothetical vaccine based on expert opinion
Enterococcus faecium	All (Bone and joint infections, BSI, Cardiac infections, Intra-abdominal infections, UTI)	70	70	5 years	6 weeks, elderly age group with highest burden	All age groups	Hypothetical vaccine based on expert opinion
Enterotoxigenic Escherichia coli (ETEC)	Diarrhoea	60	70	5 years	6 months	-	WHO Preferred Product Characteristics & Expert opinion & Advanced candidate
Extraintestinal Pathogenic Escherichia coli (ExPEC) - BSI	BSI	70	70	5 years	6 weeks, elderly age group with highest burden	All age groups	Hypothetical vaccine based on expert opinion

Extraintestinal Pathogenic Escherichia coli (ExPEC) - UTI	UTI	70	70	5 years	6 weeks, elderly age group with highest burden	All age groups	Hypothetical vaccine based on expert opinion
Group A *streptococcus* (GAS)	All (Bacterial skin infections, Bone and joint infections, BSI, Cardiac infections)	70	70	5 years	6 weeks	-	WHO Preferred Product Characteristics & Expert opinion
Haemophilus influenzae type B (Hib)	All (CNS infections, LRI and thorax infections)	59; 92; 93	90	5 years	6, 10, 14 weeks	-	Existing vaccine
Klebsiella pneumoniae - BSI	BSI	70	70	6 months	0 weeks (maternal)	-	Hypothetical vaccine based on expert opinion
Klebsiella pneumoniae - all	All (Bacterial skin infections, Bone and joint infections, BSI, Cardiac infections, CNS infections, Intra-abdominal infections, LRI and thorax infections, UTI)	70	70	5 years	6 weeks, elderly age group with highest burden	All age groups	Hypothetical vaccine based on expert opinion
Mycobacterium tuberculosis - M72[†]	Tuberculosis	50	70	10 years	10 years + boost every 10 years	-	WHO Preferred Product Characteristics & Expert opinion & Advanced candidate
Mycobacterium tuberculosis - Improved	Tuberculosis	80	70	10 years	0 weeks + boost every 10 years	-	WHO Preferred Product Characteristics & Expert opinion
Neisseria gonorrhoeae	gonorrhoea	70	70	10 years	15 years	-	WHO Preferred Product Characteristics & Expert opinion
non-typhoidal *Salmonella*	All (BSI, Cardiac infections, Diarrhoea, Typhoid, paratyphoid, and	80	70	5 years	6 weeks, 9 months	-	Hypothetical vaccine based on expert opinion

	iNTS)						
Pseudomonas aeruginosa	BSI, LRI and thorax infections	70	70	5 years	6 weeks, elderly age group with highest burden	All age groups	Hypothetical vaccine based on expert opinion
Salmonella Paratyphi	Typhoid, paratyphoid, and iNTS	70	70	5 years	9 months	-	Hypothetical vaccine based on expert opinion
Salmonella Typhi	All (BSI, Cardiac infections, Typhoid, paratyphoid, and iNTS)	85	70	15 years	9 months	-	Existing vaccine & Expert opinion
Shigella	All (Diarrhoea)	60	70	5 years	6 months	-	WHO Preferred Product Characteristics & Expert opinion & Advanced candidate
Staphylococcus aureus	All (Bacterial skin infections, Bone and joint infections, BSI, Cardiac infections, CNS infections, Intra-abdominal infections, LRI and thorax infections, UTI)	60	70	5 years	6 weeks, elderly age group with highest burden	All age groups	Hypothetical vaccine based on expert opinion
Streptococcus pneumoniae	BSI, CNS infections, Cardiac infections, LRI	29; 58; 58 (25 for LRI)	90	5 years	6, 10, 14 weeks	6, 10, 14 weeks, elderly age group with highest burden	Existing vaccine
Streptococcus pneumoniae - Improved†	BSI, CNS infections, Cardiac infections, LRI	70 (50 for LRI)	90	5 years	6 weeks	6 weeks, elderly age group with highest burden	Hypothetical vaccine based on expert opinion

† The effects of these vaccines were not added to the aggregated impact of vaccination on AMR burden by region and by infectious syndrome.

490 **Table 2. Vaccine impact on AMR burden by vaccine profile.** The estimates (median and 95% uncertainty intervals) of the vaccine avertable deaths and DALYs attributable to and associated with bacterial antimicrobial resistance in 2019 were aggregated by vaccine profile for the baseline (Table 2a) and high-potential (Table 2b) scenarios.

(Bone and joint infections = infections of bones, joints, and related organs; BSI = bloodstream infections; cardiac infections
495 = endocarditis and other cardiac infections; CNS infections = meningitis and other bacterial CNS infections; intra-abdominal infections = peritoneal and intra-abdominal infections; LRI and thorax infections = lower respiratory infections and all related infections in the thorax; bacterial skin infections = bacterial infections of the skin and subcutaneous systems; typhoid, paratyphoid, and iNTS = typhoid fever, paratyphoid fever, and invasive non-typhoidal *Salmonella* spp; UTI = urinary tract infections and pyelonephritis)

500 **Table 2a. Baseline scenario**

Pathogen	Disease presentation	Vaccine avertable deaths		Vaccine avertable DALYs	
		Associated with resistance	Attributable to resistance	Associated with resistance	Attributable to resistance
Acinetobacter baumannii - BSI	BSI	18,394 (13,542 - 25,333)	5,770 (4,318 - 7,936)	504,867 (405,735 - 646,784)	158,857 (126,938 - 201,564)
Acinetobacter baumannii - all	All (Bacterial skin infections, BSI, Cardiac infections, LRI and thorax infections, UTI)	34,588 (28,602 - 42,745)	10,887 (8,967 - 13,649)	1,027,915 (889,316 - 1,197,147)	317,057 (275,826 - 373,956)
Enterococcus faecium	All (Bone and joint infections, BSI, Cardiac infections, Intra-abdominal infections, UTI)	14,060 (12,477 - 15,807)	3,671 (3,129 - 4,245)	415,154 (373,676 - 462,667)	104,966 (91,660 - 120,836)
Enterotoxigenic Escherichia coli (ETEC)	Diarrhoea	2,856 (2,152 - 3,957)	768 (555 - 1,050)	254,870 (187,088 - 355,115)	69,430 (50,634 - 94,552)
Extraintestinal Pathogenic Escherichia coli (ExPEC) - BSI	BSI	15,298 (12,109 - 20,144)	4,012 (3,146 - 5,198)	350,136 (286,455 - 422,877)	89,100 (74,191 - 110,415)
Extraintestinal Pathogenic Escherichia coli (ExPEC) - UTI	UTI	6,803 (5,964 - 7,737)	1,796 (1,558 - 2,124)	139,597 (126,460 - 155,063)	37,179 (33,010 - 42,022)
Group A *streptococcus* (GAS)	All (Bacterial skin infections, Bone and joint infections, BSI, Cardiac infections)	793 (646 - 964)	83 (55 - 133)	69,719 (58,572 - 84,620)	6,334 (3,940 - 10,637)

Haemophilus influenzae type B (Hib)	All (CNS infections, LRI and thorax infections)	21,717 (19,415 - 24,292)	4,944 (4,067 - 6,047)	1,878,325 (1,676,258 - 2,104,200)	419,599 (346,201 - 513,491)
Klebsiella pneumoniae - BSI	BSI	27,094 (22,919 - 32,497)	8,048 (6,600 - 9,859)	2,410,978 (2,040,082 - 2,869,814)	714,166 (594,059 - 905,882)
Klebsiella pneumoniae - all	All (Bacterial skin infections, Bone and joint infections, BSI, Cardiac infections, CNS infections, Intra-abdominal infections, LRI and thorax infections, UTI)	64,591 (59,887 - 70,687)	19,332 (17,511 - 21,357)	3,670,873 (3,372,154 - 4,028,556)	1,078,066 (964,530 - 1,209,618)
Mycobacterium tuberculosis - M72	Tuberculosis	73,906 (67,292 - 81,750)	32,295 (28,353 - 37,881)	2,860,867 (2,626,788 - 3,117,069)	1,164,142 (1,011,681 - 1,349,209)
Mycobacterium tuberculosis - Improved	Tuberculosis	118,250 (107,668 - 130,801)	51,672 (45,365 - 60,610)	4,577,388 (4,202,861 - 4,987,311)	1,862,627 (1,618,690 - 2,158,734)
Neisseria gonorrhoeae	gonorrhoea	-	-	8,989 (7,155 - 11,558)	462 (434 - 490)
non-typhoidal *Salmonella*	All (BSI, Cardiac infections, Diarrhoea, Typhoid, paratyphoid, and iNTS)	1,836 (1,428 - 2,578)	395 (284 - 624)	177,910 (132,627 - 249,250)	34,574 (24,290 - 54,248)
Pseudomonas aeruginosa	BSI, LRI and thorax infections	20,721 (18,824 - 23,098)	5,282 (4,684 - 6,010)	990,472 (904,765 - 1,093,137)	253,947 (223,898 - 288,798)
Salmonella Paratyphi	Typhoid, paratyphoid, and iNTS	1,486 (880 - 2,717)	305 (164 - 585)	127,020 (73,905 - 250,668)	26,067 (14,091 - 53,697)
Salmonella Typhi	All (BSI, Cardiac infections, Typhoid, paratyphoid, and iNTS)	34,380 (27,962 - 44,734)	6,693 (5,085 - 9,212)	2,823,703 (2,264,344 - 3,549,213)	541,724 (400,042 - 759,727)
Shigella	All (Diarrhoea)	4,142 (2,882 - 6,061)	905 (560 - 1,516)	367,416 (261,735 - 556,399)	78,239 (48,195 - 130,273)
Staphylococcus aureus	All (Bacterial skin infections, Bone and joint infections, BSI, Cardiac infections, CNS infections, Intra-abdominal infections, LRI and thorax infections,	55,981 (51,732 - 60,298)	13,426 (12,135 - 15,009)	2,543,554 (2,334,156 - 2,789,137)	599,516 (538,225 - 674,447)

	UTI)				
Streptococcus pneumoniae	BSI, CNS infections, Cardiac infections, LRI	68,456 (61,877 - 75,295)	13,933 (12,122 - 16,151)	5,976,140 (5,356,670 - 6,633,156)	1,228,457 (1,074,002 - 1,416,983)
Streptococcus pneumoniae - Improved	BSI, CNS infections, Cardiac infections, LRI	123,790 (111,631 - 137,547)	25,254 (21,685 - 29,671)	10,823,583 (9,697,855 - 12,086,308)	2,231,865 (1,918,269 - 2,590,373)

Table 2b. High-potential scenario

Pathogen	Disease presentation	Vaccine avertable deaths		Vaccine avertable DALYs	
		Associated with resistance	Attributable to resistance	Associated with resistance	Attributable to resistance
Acinetobacter baumannii - BSI	BSI	116,731 (106,530 - 128,724)	36,550 (33,172 - 40,517)	3,449,712 (3,190,379 - 3,726,215)	1,088,375 (993,454 - 1,190,768)
Acinetobacter baumannii - all	All (Bacterial skin infections, BSI, Cardiac infections, LRI and thorax infections, UTI)	217,178 (204,226 - 231,539)	68,008 (63,936 - 72,754)	5,997,326 (5,692,403 - 6,349,634)	1,857,742 (1,747,874 - 1,979,071)
Enterococcus faecium	All (Bone and joint infections, BSI, Cardiac infections, Intra-abdominal infections, UTI)	100,731 (96,362 - 105,058)	26,344 (25,063 - 27,887)	2,729,853 (2,603,413 - 2,843,599)	698,106 (660,023 - 740,762)
Extraintestinal Pathogenic Escherichia coli (ExPEC) - BSI	BSI	102,850 (94,735 - 112,197)	26,483 (24,259 - 29,001)	2,670,026 (2,484,474 - 2,863,839)	695,851 (649,607 - 753,352)
Extraintestinal Pathogenic Escherichia coli (ExPEC) - UTI	UTI	49,702 (47,814 - 51,819)	13,028 (12,384 - 13,700)	1,079,093 (1,041,106 - 1,119,539)	288,533 (276,981 - 300,290)
Klebsiella pneumoniae - all	All (Bacterial skin infections, Bone and joint infections, BSI, Cardiac infections, CNS infections, Intra-abdominal infections, LRI and thorax infections, UTI)	321,641 (310,314 - 331,665)	96,929 (93,034 - 100,976)	13,670,138 (12,982,948 - 14,445,643)	4,069,401 (3,830,906 - 4,375,807)

Pseudomonas aeruginosa	BSI, LRI and thorax infections	119,080 (114,123 - 124,127)	30,474 (28,855 - 32,109)	4,824,860 (4,537,725 - 5,117,062)	1,238,693 (1,147,009 - 1,331,688)
Staphylococcus aureus	All (Bacterial skin infections, Bone and joint infections, BSI, Cardiac infections, CNS infections, Intra-abdominal infections, LRI and thorax infections, UTI)	319,070 (310,077 - 328,120)	77,108 (73,876 - 80,323)	10,612,210 (10,193,441 - 11,038,836)	2,505,468 (2,380,255 - 2,645,370)
Streptococcus pneumoniae	BSI, CNS infections, Cardiac infections, LRI	80,005 (73,620 - 87,334)	16,362 (14,497 - 18,671)	6,155,152 (5,546,498 - 6,809,012)	1,264,331 (1,110,750 - 1,450,131)
Streptococcus pneumoniae - Improved	BSI, CNS infections, Cardiac infections, LRI	143,541 (130,987 - 157,541)	29,334 (25,725 - 33,811)	11,126,629 (10,032,557 - 12,384,592)	2,292,986 (1,981,156 - 2,659,477)

Table 3. Vaccine avertable AMR burden globally and by WHO region. The estimates (median and 95% uncertainty intervals) for vaccine avertable disease burden attributable to and associated with bacterial AMR in 2019 is presented in terms of deaths and DALYs avertable by vaccination in the baseline scenario.

WHO region	Vaccine avertable deaths		Vaccine avertable DALYs	
	Associated with resistance	**Attributable to resistance**	**Associated with resistance**	**Attributable to resistance**
Africa	163,583 (154,314 - 174,201)	43,371 (39,650 - 47,043)	12,286,050 (11,439,881 - 13,202,531)	3,036,983 (2,760,087 - 3,324,409)
Americas	29,605 (27,402 - 32,706)	8,057 (7,284 - 8,954)	1,120,184 (1,053,774 - 1,196,224)	283,677 (261,588 - 306,524)
Eastern Mediterranean	60,309 (56,025 - 65,303)	17,788 (16,250 - 19,586)	4,140,114 (3,862,393 - 4,477,685)	1,132,467 (1,028,017 - 1,264,482)
Europe	29,036 (26,304 - 32,966)	9,018 (8,122 - 10,211)	912,786 (855,604 - 981,438)	285,687 (259,810 - 314,357)
South-East Asia	154,535 (141,310 - 171,302)	52,310 (45,735 - 61,119)	7,305,160 (6,617,090 - 8,161,786)	2,208,326 (1,944,432 - 2,544,221)
Western Pacific	54,756 (49,134 - 61,637)	15,644 (13,706 - 17,929)	1,919,033 (1,806,390 - 2,055,841)	500,308 (457,392 - 550,486)
Global	**492,697 (473,092 - 514,163)**	**146,241 (138,229 - 156,058)**	**27,715,403 (26,576,904 - 29,026,352)**	**7,454,056 (7,043,380 - 7,932,924)**

Figures

510 **Figure 1. Vaccine impact on AMR burden by vaccine profile.** The estimates (median and 95% uncertainty intervals) of the vaccine avertable deaths attributable to and associated with bacterial antimicrobial resistance in 2019 were aggregated by vaccine profile in the baseline scenario.



Figure 2. Vaccine impact on AMR burden by infectious syndrome. The estimates (median and 95% uncertainty intervals) of the vaccine avertable deaths attributable to and associated with bacterial antimicrobial resistance in 2019 were aggregated by infectious syndrome in the baseline scenario. (Bone+ = infections of bones, joints, and related organs; BSI = bloodstream infections; cardiac = endocarditis and other cardiac infections; CNS = meningitis and other bacterial CNS infections; intra-abdominal = peritoneal and intra-abdominal infections; LRI+ = lower respiratory infections and all related infections in the thorax; skin = bacterial infections of the skin and subcutaneous systems; TF–PF–iNTS = typhoid fever, paratyphoid fever, and invasive non-typhoidal *Salmonella* spp; UTI = urinary tract infections and pyelonephritis)



Figure 3. Vaccine avertable AMR burden by infectious syndrome and pathogen. Vaccine avertable deaths associated with AMR by infectious syndrome and pathogen in the baseline scenario.



525

Figure 4. Vaccine impact on AMR burden by WHO region. The estimates (median and 95% uncertainty intervals) of the vaccine avertable deaths attributable to and associated with bacterial antimicrobial resistance in 2019 were aggregated by WHO region in the baseline scenario.



530 # Appendix

Figure A1. Vaccine avertable AMR burden by infectious syndrome and pathogen. Vaccine avertable AMR burden (deaths and DALYs averted) by infectious syndrome and pathogen in the baseline scenario. (A) Vaccine avertable deaths associated with AMR by infectious syndrome and pathogen. (B) Vaccine avertable deaths attributable to AMR by infectious syndrome and pathogen. (C) Vaccine
535 avertable DALYs associated with AMR by infectious syndrome and pathogen. (D) Vaccine avertable DALYs attributable to AMR by infectious syndrome and pathogen.

(A)



(B)


Klebsiella pneumoniae
(21.81%)
Pseudomonas aeruginosa
(9.33%)
Staphylococcus aureus
(20.50%)
Haemophilus influenzae
(10.44%)
Acinetobacter baumannii
(11.07%)
Streptococcus pneumoniae
(26.84%)
Streptococcus pneumoniae
(4.76%)
Staphylococcus aureus
(8.46%)
Others
(12.44%)
LRI and thorax infections
(26.8%)
Klebsiella pneumoniae
(42.23%)
Bloodstream Infections
(21.0%)
Others
(16.6%)
(100.00%)
Escherichia coli
(13.17%)
Tuberculosis
(35.6%)
Acinetobacter baumannii
(18.94%)
Mycobacterium tuberculosis
(100.00%)

540

(C)


Klebsiella pneumoniae
(18.04%)
Pseudomonas aeruginosa
(7.10%)
Staphylococcus aureus
(16.12%)
Haemophilus influenzae
(14.04%)
Acinetobacter baumannii
(4.18%)
Streptococcus pneumoniae
(11.10%)
Staphylococcus aureus
(4.88%)
Others
(13.90%)
Streptococcus pneumoniae
(40.52%)
LRI and thorax infections
(40.2%)
Klebsiella pneumoniae
(54.80%)
Bloodstream Infections
(20.2%)
Tuberculosis
(16.6%)
Others
(23.0%)
Escherichia coli
(6.27%)
Acinetobacter baumannii
(9.04%)
(100.00%)
Mycobacterium tuberculosis
(100.00%)

(D)


Klebsiella pneumoniae
(22.25%)
Pseudomonas aeruginosa
(7.69%)
Staphylococcus aureus
(16.03%)
Haemophilus influenzae
(13.31%)
Acinetobacter baumannii
(5.42%)
Streptococcus pneumoniae
Staphylococcus aureus
(4.38%)
Others
(10.70%)
Streptococcus pneumoniae
(35.30%)
LRI and thorax infections
(35.5%)
Klebsiella pneumoniae
(60.08%)
Bloodstream Infections
(20.4%)
Others
(18.9%)
Escherichia coli
(5.90%)
Acinetobacter baumannii
(10.52%)
Tuberculosis
(25.2%)
(100.00%)
Mycobacterium tuberculosis
(100.00%)